Profile data is unavailable for this security.
About the company
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
- Revenue in USD (TTM)5.98m
- Net income in USD-197.34m
- Incorporated2019
- Employees214.00
- LocationPrime Medicine Inc60 First St.CAMBRIDGE 02141United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://primemedicine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Keros Therapeutics Inc | 246.72m | 64.45m | 525.24m | 82.00 | 11.17 | 0.9956 | 7.97 | 2.13 | 1.54 | 1.54 | 6.07 | 17.32 | 0.3732 | -- | 127.17 | 1,459,870.00 | 9.75 | -36.26 | 10.16 | -38.17 | -- | -- | 26.12 | -2,307.89 | -- | -- | 0.00 | -- | 2,250.99 | -18.71 | -22.46 | -- | 48.10 | -- |
| Perspective Therapeutics Inc | 1.08m | -106.31m | 527.42m | 138.00 | -- | 1.42 | -- | 490.63 | -1.46 | -1.46 | 0.0147 | 3.26 | 0.0031 | -- | 5.43 | 7,789.86 | -31.00 | -- | -33.37 | -- | -- | -- | -9,889.68 | -- | -- | -- | 0.0067 | -- | 1.39 | -- | -109.13 | -- | -- | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 528.95m | 41.00 | -- | 2.34 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -237.32m | 548.26m | 166.00 | -- | 14.58 | -- | -- | -2.68 | -2.68 | 0.00 | 0.3916 | 0.00 | -- | -- | 0.00 | -94.37 | -45.17 | -169.95 | -49.01 | -- | -- | -- | -- | -- | -2.19 | 0.4541 | -- | -- | -- | -30.94 | -- | -- | -- |
| Altimmune Inc | 20.00k | -83.92m | 555.14m | 59.00 | -- | 2.53 | -- | 27,757.06 | -1.07 | -1.07 | 0.0003 | 1.94 | 0.0001 | -- | 0.0314 | 338.98 | -45.82 | -42.36 | -48.64 | -45.46 | -- | -- | -419,575.00 | -3,193.88 | -- | -- | 0.0722 | -- | -95.31 | -67.83 | -7.48 | -- | -- | -- |
| Gossamer Bio Inc | 44.05m | -156.16m | 563.60m | 144.00 | -- | -- | -- | 12.79 | -0.6872 | -0.6872 | 0.1939 | -0.356 | 0.1574 | -- | 5.57 | 305,909.70 | -55.80 | -51.30 | -69.95 | -58.28 | -- | -- | -354.50 | -822.21 | -- | -15.04 | 1.71 | -- | -- | -- | 68.56 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -67.45m | 566.79m | 55.00 | -- | 2.84 | -- | -- | -1.19 | -1.19 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -28.49 | -18.88 | -29.66 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -314.85m | 572.23m | 479.00 | -- | 2.62 | -- | -- | -3.44 | -3.44 | 0.00 | 2.64 | 0.00 | -- | -- | 0.00 | -67.19 | -33.04 | -75.03 | -35.07 | -- | -- | -- | -- | -- | -- | 0.2565 | -- | -- | -- | -14.60 | -- | 0.4456 | -- |
| MeiraGTx Holdings PLC | 27.42m | -168.69m | 579.53m | 409.00 | -- | -- | -- | 21.14 | -2.11 | -2.11 | 0.343 | -0.5039 | 0.1121 | -- | 9.01 | 71,960.63 | -69.00 | -30.69 | -121.96 | -38.41 | 41.01 | -- | -615.27 | -428.39 | 0.2235 | -36.10 | 2.21 | -- | 137.42 | 20.15 | -75.89 | -- | -11.21 | -- |
| Prime Medicine Inc | 5.98m | -197.34m | 584.85m | 214.00 | -- | 3.61 | -- | 97.85 | -1.44 | -1.44 | 0.0434 | 0.8975 | 0.0167 | -- | -- | 27,929.91 | -54.98 | -64.35 | -61.20 | -77.73 | -- | -- | -3,301.64 | -8,356.07 | -- | -- | 0.00 | -- | -- | -- | 1.14 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -117.30m | 593.48m | 45.00 | -- | 2.75 | -- | -- | -2.29 | -2.29 | 0.00 | 3.22 | 0.00 | -- | -- | 0.00 | -44.05 | -- | -48.27 | -- | -- | -- | -- | -- | -- | -- | 0.1221 | -- | -- | -- | -112.73 | -- | 50.55 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -25.94m | 601.10m | 15.00 | -- | 9.68 | -- | -- | -0.2869 | -0.2869 | 0.00 | 0.3648 | 0.00 | -- | -- | 0.00 | -66.47 | -125.08 | -84.33 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| LB Pharmaceuticals Inc | 0.00 | -18.80m | 603.64m | 16.00 | -- | 1.95 | -- | -- | -0.82 | -0.82 | 0.00 | 12.26 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -905.61 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 0.00 | -71.11m | 630.02m | 45.00 | -- | 2.60 | -- | -- | -1.14 | -1.14 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -28.80 | -35.63 | -30.41 | -38.94 | -- | -- | -- | -314.68 | -- | -- | 0.00 | -- | 2,752.05 | -- | 90.01 | -- | -20.09 | -- |
| Kura Oncology Inc | 104.03m | -216.88m | 643.93m | 192.00 | -- | 2.65 | -- | 6.19 | -2.48 | -2.48 | 1.19 | 2.79 | 0.1844 | -- | -- | 541,817.70 | -38.45 | -26.38 | -44.88 | -28.06 | -- | -- | -208.48 | -1,266.72 | -- | -- | 0.0384 | -- | -- | -- | -13.99 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Prime Medicine Inc's reporting currency: US Dollar USD
26.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2025 | 9.22m | 5.34% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.60m | 3.25% |
| ARK Investment Management LLCas of 30 Sep 2025 | 5.48m | 3.18% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 5.13m | 2.97% |
| Farallon Capital Management LLCas of 30 Sep 2025 | 4.75m | 2.75% |
| Amova Asset Management Americas, Inc.as of 30 Sep 2025 | 3.63m | 2.10% |
| Amova Asset Management Co., Ltd.as of 31 Dec 2025 | 3.25m | 1.88% |
| Casdin Capital LLCas of 30 Sep 2025 | 3.17m | 1.84% |
| Woodline Partners LPas of 30 Sep 2025 | 3.00m | 1.74% |
| RA Capital Management LPas of 30 Sep 2025 | 3.00m | 1.74% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
